Carcinova Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
- Paid Up Capital ₹ 6.50 Cr
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 19.89 Cr
- Revenue Growth 71.36%
- Profit Growth 458.59%
- Ebitda 63.88%
- Net Worth 170.04%
- Total Assets 19.94%
About Carcinova
Carcinova Private Limited (CPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 June 2017 (Seven years and seven months 16 days old ). Its registered office is in Cuttack, Odisha, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 6.50 Cr.
The company currently has active open charges totaling ₹19.89 Cr.
Prangyan Mishra and Kshitish Mishra serve as directors at the Company.
Company Details
-
Location
Cuttack, Odisha, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85190OR2017PTC027247
-
Company No.
027247
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Jun 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Carcinova?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kshitish Mishra
|
Managing Director | 24-Jun-2017 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Prangyan Mishra
|
Director | 24-Jun-2017 | Current |
Financial Performance of Carcinova.
Carcinova Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 71.36% increase. The company also saw a substantial improvement in profitability, with a 458.59% increase in profit. The company's net worth Soared by an impressive increase of 170.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carcinova?
In 2023, Carcinova had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Uncan Pharmaceuticals Private LimitedPrangyan Mishra is a mutual person
Charges (Loans)
₹19.89 Cr
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 19.89 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2021 | Indian Bank | ₹2.00 Cr | Open |
| 26 Sep 2019 | Indian Bank | ₹17.89 Cr | Open |
How Many Employees Work at Carcinova?
Carcinova has a workforce of 51 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carcinova, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carcinova's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.